Power3's BC-SeraPro Test Highlighted in Woman’s Day Magazine

Article Features Blood Serum Diagnostic For Early Detection of Breast Cancer

The Woodlands, TX -- Power3 Medical Products, Inc. (OTCBB: PWRM), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, was highlighted in an article in the January issue of Woman’s Day Magazine in the “Health Your Health” section.

The article, written by Barbara Brody, highlights BC-SeraPro™, Power3’s blood serum diagnostic test for the early detection of breast cancer. Brody writes, “A recent study found that the test, which screens for proteins that indicate the presence of cancer cells, can accurately detect cancer 80 to 90 percent of the time.” Power3 launched the BC-SeraPro diagnostic test in the Middle East through a distribution agreement in October 2007. The company plans to offer BC-SeraPro in high-risk cancer centers in the United States later this year.

“We are excited to be featured in Woman’s Day magazine,” said Steve Rash, Chief Executive Officer of Power3. “We believe BC-SeraPro will be a critical new test for women, one that will supplement and enhance the breast cancer detection methods that are currently offered. We are happy to be able to increase awareness of the importance of early detection by inclusion in a publication that reaches such large numbers of women.”

Woman’s Day has a circulation of 4.3 million, according to Audit Bureau of Circulations.

About Power3 Medical Products
Power3 Medical Products, Inc. (OTCBB: PWRM), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro, in twelve Middle Eastern countries before the end of 2007. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas, and recently announced an agreement forming a joint venture (CRO) with NeoGenomics, Inc. (NASDAQ: NGNM - News) of Fort Myers, Florida, to commercialize Power3’s portfolio of IP, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s, and Parkinson’s Diseases.